Business Wire

PM-MIKATI-MEDIA-OFFICE

Share
Lebanon’s PM Mikati Media Office Take on "Pandora Papers"

The Media Office of Lebanon’s Prime Minister Najib Mikati has issued the following statement:

In the context of the recently revealed “Pandora Papers” , it would be important to emphasize the fact that the origin of the wealth of Lebano n’s Prime Minister Najib Mikati is derived from over 20 years of sustained work in the telecom sector, that culminated in 2005, with the listing of the telecom company – (that the Mikati family used to own) – on the main board of the London Stock Exchange ; and its subsequent merger with the Johannesburg-based telecom leader MTN . Therefore, the source of wealth of the Mikati family had been well-scrutinized by the concerned bodies and entities that were piloting the Initial Public Offering (IPO) - thus certifying that the same source of wealth was well-documented, legal, legitimate and audited; and that it derived from the family business’ global activities that preceded the entry of Najib Mikati into politics in Lebanon.

The Monaco property, among other assets around the world, specifically mentioned in the “Papers”, is not the only property owned via a corporate entity. Most family assets and properties fall under the same corporate principle of management and good governance. It is a common and lawful business practice that, in case many family members share the same assets, to organize the ownership via legal entities that offer flexibility as well as corporate, financial and fiscal advantages.

In addition, all the assets and properties belonging to PM Najib Mikati have been duly disclosed to the Constitutional Council in Lebanon, as per the prevailing laws, rules and regulations, since he entered politics.

It is worth highlighting that not all people mentioned in the “Pandora Papers” are necessarily accused of wrongdoings. Also, not all fortunes amassed ought to have necessarily happened at the expense of the common good and needy people.

Regrettably, the underlying logic behind the “Papers” drifted toward transforming most, if not all, of those mentioned into “suspicious” individuals &/or companies, by the mere fact of being listed in there - a logic that goes against the free-market business practices and good governance, in liberal economies, principles that the Mikati family defends.

Since its inception, M1 Group (the Mikati family business) – and all of its subsidiaries around the world – have upheld a separation between public and private. They continue to be fully compliant with global standards; retain world-class auditors; and operate in multiple jurisdictions.

The group respects the right of board members &/or senior executives to run for or hold public office. However, politics &/or public office holders do not influence the group’s guiding principles and business operations; and vice-versa.

At all times, PM Mikati and M1 Group respect the rule of law and abide by it everywhere. All rights reserved.

-Ends-

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release

Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline

Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release

Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release

In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically

Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release

Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea

Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye